Sir Gregory Winter joins Covagen’s Scientific Advisory Board

22-Sep-2011 - Switzerland

Covagen announced that Sir Gregory Winter is joining its Scientific Advisory Board. Sir Gregory Winter is a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge, and a Fellow of Trinity College Cambridge (UK). He has served LMB as a Head of Division, Deputy Director and Acting Director. His scientific career has almost entirely been based in Cambridge where his work included protein sequencing, nucleic acid sequencing and protein engineering. He is mainly known for pioneering the development of technologies to make humanized antibodies (by grafting hypervariable regions from rodent antibodies to human antibodies) and human antibodies from large antibody repertories.

He was a Founder and Director of Cambridge Antibody Technology (acquired by Astra Zeneca), a Founder and Director of Domantis (acquired by GSK) and more recently a Founder and Director of Bicycle Therapeutics. Sir Gregory Winter has received numerous international prizes and awards, and in 2004 was knighted for his services to Molecular Biology.

Other news from the department people

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance